ZOETIS INC. ZTS
i
Market dataready · fetched 2026-11-12T02:39:21.083Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:19:08.96259647Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T02:39:20.564426+00:00
ZOETIS INC. options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 87.22 | 33.2% | 6.1% | 78.52 | 36.9% | 5.7% |
| 25Δ | 86.19 | 32.7% | 5.0% | 79.87 | 34.5% | 4.2% |
| 30Δ | 85.16 | 32.2% | 3.9% | 80.58 | 35.2% | 3.8% |
| 35Δ | 84.52 | 32.2% | 3.5% | 81.22 | 36.2% | 3.4% |
| 40Δ | 83.96 | 32.3% | 3.2% | 81.87 | 37.2% | 3.1% |
| 45Δ | 83.40 | 32.5% | 2.8% | 82.51 | 38.2% | 2.8% |
| 50Δ | 82.83 | 32.6% | 2.5% | 83.15 | 39.2% | 2.4% |
| 55Δ | 82.27 | 32.7% | 2.2% | 83.79 | 40.2% | 2.1% |
| 60Δ | 81.71 | 32.9% | 1.9% | 84.44 | 41.2% | 1.7% |
| 65Δ | 81.14 | 33.0% | 1.5% | 85.13 | 42.2% | 1.4% |
| 70Δ | 80.58 | 33.1% | 1.2% | 86.19 | 42.6% | 1.2% |
| 75Δ | 80.01 | 33.2% | 0.9% | 87.25 | 43.0% | 0.9% |
| 80Δ | 88.30 | 43.4% | 0.7% | |||
20Δ
- Pseudo strike
- 87.22
- IV
- 33.2%
- B/E move
- 6.1%
- Pseudo strike
- 78.52
- IV
- 36.9%
- B/E move
- 5.7%
25Δ
- Pseudo strike
- 86.19
- IV
- 32.7%
- B/E move
- 5.0%
- Pseudo strike
- 79.87
- IV
- 34.5%
- B/E move
- 4.2%
30Δ
- Pseudo strike
- 85.16
- IV
- 32.2%
- B/E move
- 3.9%
- Pseudo strike
- 80.58
- IV
- 35.2%
- B/E move
- 3.8%
35Δ
- Pseudo strike
- 84.52
- IV
- 32.2%
- B/E move
- 3.5%
- Pseudo strike
- 81.22
- IV
- 36.2%
- B/E move
- 3.4%
40Δ
- Pseudo strike
- 83.96
- IV
- 32.3%
- B/E move
- 3.2%
- Pseudo strike
- 81.87
- IV
- 37.2%
- B/E move
- 3.1%
45Δ
- Pseudo strike
- 83.40
- IV
- 32.5%
- B/E move
- 2.8%
- Pseudo strike
- 82.51
- IV
- 38.2%
- B/E move
- 2.8%
50Δ
- Pseudo strike
- 82.83
- IV
- 32.6%
- B/E move
- 2.5%
- Pseudo strike
- 83.15
- IV
- 39.2%
- B/E move
- 2.4%
55Δ
- Pseudo strike
- 82.27
- IV
- 32.7%
- B/E move
- 2.2%
- Pseudo strike
- 83.79
- IV
- 40.2%
- B/E move
- 2.1%
60Δ
- Pseudo strike
- 81.71
- IV
- 32.9%
- B/E move
- 1.9%
- Pseudo strike
- 84.44
- IV
- 41.2%
- B/E move
- 1.7%
65Δ
- Pseudo strike
- 81.14
- IV
- 33.0%
- B/E move
- 1.5%
- Pseudo strike
- 85.13
- IV
- 42.2%
- B/E move
- 1.4%
70Δ
- Pseudo strike
- 80.58
- IV
- 33.1%
- B/E move
- 1.2%
- Pseudo strike
- 86.19
- IV
- 42.6%
- B/E move
- 1.2%
75Δ
- Pseudo strike
- 80.01
- IV
- 33.2%
- B/E move
- 0.9%
- Pseudo strike
- 87.25
- IV
- 43.0%
- B/E move
- 0.9%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 88.30
- IV
- 43.4%
- B/E move
- 0.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 37.16% | |
| 39.06% | |
| 38.84% | |
| 37.92% | |
| 38.38% | |
| 37.57% | |
| 38.36% | |
| 37.63% | |
| 37.79% | |
| 37.66% | |
| 37.46% | |
| 37.59% | |
| 38.96% | |
| 37.12% | |
| 37.97% | |
| 39.45% | |
| 39.06% | |
| 38.11% | |
| 37.97% | |
| 38.36% | |
| 39.17% | |
| 38.03% | |
| 39.33% | |
| 37.65% | |
| 38.93% | |
| 39.89% | |
| 39.20% | |
| 40.50% | |
| 38.66% | |
| 51.24% | |
| 40.67% | |
| 39.86% | |
| 41.20% | |
| 42.15% | |
| 42.11% | |
| 42.52% | |
| 43.01% | |
| 43.70% | |
| 44.15% | |
| 43.10% | |
| 44.81% |
Drug Manufacturers - Specialty & Generic
ACB
Aurora Cannabis Inc. produces and distributes medical cannabis products globally. The company is headquartered in Edmonton, Canada.
More →AKBA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is…
More →ALKS
Alkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in…
More →AMLX
Amylyx Pharmaceuticals Inc (AMLX) is an innovative biopharmaceutical company at the forefront of developing transformative therapies for neurodegenerative diseases, particularly…
More →AMPH
Description unavailable
More →AMRX
Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic…
More →